BBOT — BridgeBio Oncology Therapeutics Inc. stock price, charts and financials

QT24BridgeBio Oncology Therapeutics Inc.

Latest market price

8.87

+0.62+7.52%

Overview Short InterestFilings

BBOTQT24BridgeBio Oncology Therapeutics Inc.·NASDAQ

Overview Short InterestFilings

8.87+7.52%

Loading chart...

Screen all →

OCUL+2.26%$8.59 MESO+2.28%$14.80 AUPH+2.47%$14.93 TYRA+1.53%$32.53 URGN+3.45%$39.92 IOVA+0.93%$4.36 STOK+7.14%$31.67 TSHA+7.27%$6.20

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	32.01%	Shs Outstand	80.11M	Perf Week	3.26%

Market Cap	710.55M	Forward P/E	-	EPS next Y	-2.18	Insider Trans	0.00%	Shs Float	452.99K	Perf Month	5.47%

Enterprise Value	461.55M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	7.10%	Perf Quarter	4.85%

Income	-134.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	12.29	Perf Half Y	-26.27%

Sales	0.00	P/B	1.91	EPS next Y	4.82%	ROA	-36.90%	Short Interest	5.69M	Perf YTD	-29.15%

Book/sh	4.64	P/C	2.82	EPS next 5Y	-	ROE	-61.49%	52W High	14.87 -40.35%	Perf Year	-

Cash/sh	3.15	P/FCF	-	EPS past 3/5Y	-	ROIC	-45.04%	52W Low	7.00 26.71%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	6.86% 6.93%	Perf 5Y	-

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-11479.35%	Oper. Margin	0.00%	ATR (14)	0.56	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	6.16	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	56.47	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	6.16	EPS Q/Q	99.08%	SMA20	3.19%	Beta	1.32	Target Price	23.00

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	8.19%	Rel Volume	1.22	Prev Close	8.25

Employees	92	LT Debt/Eq	0.00	Earnings	Aug 11	SMA200	-12.19%	Avg Volume	416.42K	Price	8.87

IPO Date	Aug 12, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	6.24% -	Net Debt/EBITDA	0.30	Volume	507,088	Change	7.52%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-11-26	Initiated	Canaccord	Buy	$23
Feb-10-26	Initiated	Stifel	Buy	$23
Jan-09-26	Initiated	Raymond James	Outperform	$24
Jan-08-26	Reiterated	Morgan Stanley		$20 → $18
Dec-05-25	Initiated	Morgan Stanley	Overweight	$20
Sep-17-25	Initiated	Leerink	Outperform	$25
Sep-15-25	Initiated	H.C	Buy	$27
Sep-04-25	Initiated	Oppenheimer	Outperform	$23
Aug-15-25	Initiated	Piper Sandler	Overweight	$21

Latest News

Jul-28-26

Jul-28-2601:15AM

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Receives $24.80 Average PT from Brokeragesdefenseworld.net

Jul-13-26

Jul-13-2611:20AM

BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentimentseekingalpha.com

Jul-08-26

Jul-08-2602:30PM

Which stocks are gapping on Wednesday?ChartMill

Jun-22-26

Jun-22-2601:34PM

Oppenheimer Assumes BridgeBio Oncology at Outperform, Announces Price Target of $22Benzinga

Company

BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021
Total Revenue	0	0	0	0	0
Cost of Goods Sold Incl. D&A	0	0	0	0	0
Gross Profit	0	0	0	0	0
Selling, General and Administrative Excl. Other	25	8	8	0	0
Research and Development	121	73	56	0	0
Other Operating Expense	0	0	1	0	0
Operating Income	-146	-81	-65	0	0
Interest Expense	0	0	0	0	0
Unusual Expense	—	—	—	—	—
Non-Operating Income (Expense)	12	7	0	0	0
Net Income Before Taxes	-134	-74	-65	0	0
Income Taxes	0	0	0	0	0
Consolidated Net Income	-134	-74	-65	0	0
Net Income From Continuing Operations	-134	8	-65	0	0
Net Income	-134	-74	-65	0	0
EPS (Recurring)	-4.30	0.46	-3.16	0.00	-0.00
EPS (Basic, Before Extraordinaries)	-4.30	0.46	-3.16	0.00	-0.00
EPS (Diluted)	-4.30	0.46	-3.16	-0.00	-0.00
EBITDA	-145	-81	-65	0	0
Other After Tax Adjustments	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—
Price To Earnings Ratio	—	22.83	—	—	—
Price To Sales Ratio	—	—	—	—	—
Gross Margin	—	—	—	—	—
Operating Margin	—	—	—	—	—
Net Margin	—	—	—	—	—
Shares Outstanding	31	17	20	20	20
Market Capitalization	388	179	—	—	—
Operating Lease Expense	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	#Shares	Value ($)	#Shares Total	SEC Form 4
Chen Bihua	director, 10 percent owner:	Aug 11 '25	Option Exercise	4,172,126	417	4,681,126	Aug 13
Holman Albert A III	other: Former Director	Aug 11 '25	Option Exercise	30,000	0	30,000	Aug 11
McKenna Mark C.	other: Former Director	Aug 11 '25	Option Exercise	30,000	0	30,000	Aug 11
Schmid John P.	other: Former Director	Aug 11 '25	Option Exercise	30,000	0	30,000	Aug 11

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.